These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35129294)

  • 1. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials.
    Haduong JH; Heske CM; Allen-Rhoades W; Xue W; Teot LA; Rodeberg DA; Donaldson SS; Weiss A; Hawkins DS; Venkatramani R
    Pediatr Blood Cancer; 2022 Apr; 69(4):e29511. PubMed ID: 35129294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
    Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
    Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
    Harel M; Ferrer FA; Shapiro LH; Makari JH
    Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
    Malempati S; Hawkins DS
    Pediatr Blood Cancer; 2012 Jul; 59(1):5-10. PubMed ID: 22378628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
    Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
    J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.
    Oberoi S; Crane JN; Haduong JH; Rudzinski ER; Wolden SL; Dasgupta R; Linardic CM; Weiss AR; Venkatramani R;
    Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30556. PubMed ID: 37430436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 12. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Hawkins DS; Skapek SX; Parham DM; Teot LA
    Arch Pathol Lab Med; 2015 Oct; 139(10):1281-7. PubMed ID: 25989287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.
    Shenoy A; Alvarez E; Chi YY; Li M; Shern JF; Khan J; Hiniker SM; Granberg CF; Hawkins DS; Parham DM; Teot LA; Rudzinski ER
    Eur J Cancer; 2021 Jan; 143():127-133. PubMed ID: 33302115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
    Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.
    Crane JN; Xue W; Qumseya A; Gao Z; Arndt CAS; Donaldson SS; Harrison DJ; Hawkins DS; Linardic CM; Mascarenhas L; Meyer WH; Rodeberg DA; Rudzinski ER; Shulkin BL; Walterhouse DO; Venkatramani R; Weiss AR
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29644. PubMed ID: 35253352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.